

# Laquinimod Supports Remyelination in Non-Supportive Environments

Stella Nyamoya <sup>1,2†</sup>, Julia Steinle <sup>2†</sup>, Uta Chrzanowski <sup>3</sup>, Joel Kaye <sup>4</sup>, Christoph Schmitz <sup>3</sup>, Cordian Beyer <sup>2</sup> and Markus Kipp <sup>2,5,\*</sup>

<sup>1</sup> Institute of Anatomy, Rostock University Medical Center, 18057 Rostock, Germany; Stella.Nyamoya@rwth-aachen.de

<sup>2</sup> Institute of Neuroanatomy and JARA-BRAIN, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany; Julia.Steinle@rwth-aachen.de (J.S.); CBeyer@ukaachen.de (C.B.)

<sup>3</sup> Department of Anatomy II, Ludwig-Maximilians-University of Munich, 80336 Munich, Germany; Uta.Chrzanowski@med.uni-muenchen.de (U.C.); Christoph\_Schmitz@med.uni-muenchen.de (C.S.)

<sup>4</sup> AyalaPharma, VP Research & Nonclinical Development, Rehovot, 7670104, Israel; Joel Kaye joel.k@ayalapharma.com


<sup>5</sup> Centre for Transdisciplinary Neurosciences, Rostock University Medical Center, 18057 Rostock, Germany

\* Correspondence: Markus.Kipp@med.uni-rostock.de; Tel.: + 49 (0) 381 494 8401

† These authors contributed equally to this work

## Supplementary Materials:

### Supplemental Figure



**Figure S1:** Percentage of proliferating (Ki67<sup>+</sup>) oligodendrocytes (OLIG2<sup>+</sup>) of control, showing results after 4 weeks of cuprizone intoxication, and 6 and 8 weeks of cuprizone intoxication for vehicle or laquinimod groups.